Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-Bromoindirubin-3'-oxime (BIO) is a cell-permeable, synthetic small-molecule derivative of 6-bromoindirubin, a natural compound found in Tyrian purple from the Mediterranean mollusk Hexaplex trunculus. It acts as a potent, selective, reversible, and ATP-competitive inhibitor of glycogen synthase kinase-3 alpha/beta (GSK-3α/β) with an IC50 of approximately 5 nM. By inhibiting GSK-3, BIO activates the Wnt/β-catenin signaling pathway, which has been shown to maintain self-renewal and pluripotency in human and mouse embryonic stem cells. Additionally, BIO exhibits weaker inhibitory activity against cyclin-dependent kinases CDK1 and CDK5, and acts as a pan-JAK inhibitor. It is widely used as a research tool to study stem cell biology, cellular differentiation, and various disease models including cancer and neurodegenerative disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-bromo-indirubin-3'-oxime.